Global Hepatitis B Human Immunoglobulin Market Size By Type (100IU, 200IU), By Application (Measles Prevention, Prevention of Hepatitis B Virus Infection), By Region, And Segment Forecasts, 2023 to 20...

The Global Hepatitis B Human Immunoglobulin Market was valued at USD 1.4 billion in 2023 and is projected to reach USD 2.5 billion by 2031, growing at a CAGR of 7.6% during the forecast period of 2023–2031. The market is driven by the increasing prevalence of hepatitis B infections, rising awareness of post-exposure prophylaxis (PEP), and growing government initiatives toward hepatitis elimination. Hepatitis B immunoglobulin (HBIG) is a critical passive immunization product administered to prevent the transmission of the hepatitis B virus (HBV), especially in perinatal, sexual, and occupational exposure scenarios.

Drivers:

1. Rising Incidence of Hepatitis B:

The persistent global burden of hepatitis B, particularly in Asia-Pacific and sub-Saharan Africa, has increased the need for effective immunoprophylaxis solutions such as HBIG.

2. Increased Immunization Efforts:

Governments and health organizations such as WHO and CDC are actively promoting immunization programs that integrate HBIG for immediate protection in high-risk exposures, propelling market demand.

3. Expansion of Blood Plasma Collection Facilities:

A rise in plasma collection centers, supported by advancements in purification and fractionation technologies, is ensuring a stable supply chain for HBIG products.

Restraints:

1. High Production Costs and Limited Accessibility:

HBIG production relies on human plasma, making it cost-intensive. Limited availability of donors and complex purification processes restrict accessibility in low-income regions.

2. Risk of Blood-Borne Contamination:

Despite rigorous screening, the risk of transmitting other pathogens through plasma-derived products remains a safety concern, especially in countries with less stringent regulatory oversight.

Opportunity:

1. Technological Advancements in Immunoglobulin Purification:

Innovations in recombinant technology and purification methods are anticipated to enhance product efficacy, safety, and scalability, opening new avenues for market expansion.

2. Unmet Needs in Emerging Economies:

Growing healthcare awareness, improving infrastructure, and higher government health spending in Latin America, Southeast Asia, and Africa present lucrative opportunities for market penetration.

Market by System Type Insights:

Based on system type, the Intramuscular Injection segment held the largest market share in 2023. Intramuscular HBIG is widely used due to its effectiveness in perinatal transmission prevention and for post-exposure prophylaxis. The Intravenous Injection segment is expected to register the fastest growth during the forecast period, driven by increased use in liver transplant patients and rapid immune response requirements.

Market by End-use Insights:

In terms of end-use, the Hospitals segment dominated the market in 2023, driven by rising hospital-based immunization and emergency care services. Specialty Clinics and Ambulatory Surgical Centers (ASCs) are also witnessing steady growth due to the decentralization of healthcare services and greater accessibility to immunoglobulin therapies.

Market by Regional Insights:

Geographically, Asia-Pacific led the global hepatitis B human immunoglobulin market in 2023, owing to the high prevalence of HBV infections, large birth cohorts, and increasing government immunization initiatives. North America is expected to see strong growth during the forecast period due to advanced healthcare infrastructure and high awareness. Meanwhile, Europe remains a significant market due to its robust regulatory support and national hepatitis control programs.

Competitive Scenario:

Key players in the market include Grifols S.A., CSL Behring, Kedrion Biopharma, Biotest AG, Octapharma AG, Bharat Serums and Vaccines Ltd., Shanghai RAAS, Emergent BioSolutions Inc., Green Cross Corporation, and China Biologic Products Holdings Inc. These companies are emphasizing on product approvals, capacity expansion, and geographic outreach.

Key Market Developments:

In 2023, CSL Behring launched a new plasma collection facility in the U.S. to scale up HBIG production.

Grifols S.A. acquired several donor centers in Europe in 2024 to enhance supply chain capacity.

In 2025, Bharat Serums and Vaccines Ltd. received regulatory approval in Southeast Asia to distribute its HBIG product.

Scope of Work – Global Hepatitis B Human Immunoglobulin Market

FAQs:

1) What is the current market size of the Global Hepatitis B Human Immunoglobulin Market?

The market size in 2023 is estimated at USD 1.4 billion.

2) What is the major growth driver of the Global Hepatitis B Human Immunoglobulin Market?

The major driver is the rising incidence of hepatitis B infections and increasing post-exposure prophylaxis demand.

3) Which is the largest region during the forecast period in the Global Hepatitis B Human Immunoglobulin Market?

Asia-Pacific holds the largest market share due to high HBV prevalence and immunization efforts.

4) Which segment accounted for the largest market share in the Global Hepatitis B Human Immunoglobulin Market?

The Intramuscular Injection segment led the market in 2023.

5) Who are the key market players in the Global Hepatitis B Human Immunoglobulin Market?

Key players include Grifols S.A., CSL Behring, Kedrion Biopharma, Biotest AG, Octapharma AG, and others.

Let me know if you’d like a version of this report formatted as a PDF or DOCX.